Colony-stimulating factors detected in tumor cells and voided urine are potential prognostic markers for patients with muscle-invasive bladder cancer undergoing radical cystectomy
暂无分享,去创建一个
K. Shimada | M. Miyake | N. Tanaka | Y. Tatsumi | Y. Nakai | K. Fujimoto | T. Fujii | S. Hori | Y. Morizawa | Tomomi Fujii
[1] S. Saxena,et al. Predictive role of serum and urinary cytokines in invasion and recurrence of bladder cancer , 2017, Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine.
[2] I. Hong. Stimulatory versus suppressive effects of GM-CSF on tumor progression in multiple cancer types , 2016, Experimental & Molecular Medicine.
[3] M. Wirth,et al. Decreased Overall and Bladder Cancer-Specific Mortality with Adjuvant Chemotherapy After Radical Cystectomy: Multivariable Competing Risk Analysis. , 2016, European urology.
[4] K. Shimada,et al. Extended resection including adjacent organs and Ki-67 labeling index are prognostic factors in patients with retroperitoneal soft tissue sarcomas , 2016, World Journal of Surgical Oncology.
[5] L. Liao,et al. Effect of Granulocyte-Macrophage Colony-Stimulating Factor on Prevention and Treatment of Invasive Fungal Disease in Recipients of Allogeneic Stem-Cell Transplantation: A Prospective Multicenter Randomized Phase IV Trial. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[6] S. Corey,et al. G-CSF and GM-CSF in Neutropenia , 2015, The Journal of Immunology.
[7] H. Miyake,et al. Performance status as a significant prognostic predictor in patients with urothelial carcinoma of the bladder who underwent radical cystectomy , 2015, International journal of urology : official journal of the Japanese Urological Association.
[8] Minyong Kang,et al. Prognostic factors for conditional survival in patients with muscle-invasive urothelial carcinoma of the bladder treated with radical cystectomy , 2015, Scientific Reports.
[9] A. Pathak,et al. G-CSF utilization rate and prescribing patterns in United States: associations between physician and patient factors and GCSF use , 2014, Cancer medicine.
[10] L. Terracciano,et al. GM-CSF Production by Tumor Cells Is Associated with Improved Survival in Colorectal Cancer , 2014, Clinical Cancer Research.
[11] M. Saito,et al. Prognostic impact of preoperative hematological disorders and a risk stratification model in bladder cancer patients treated with radical cystectomy , 2014, International journal of urology : official journal of the Japanese Urological Association.
[12] H. Radzun,et al. Tumor-associated macrophages are involved in tumor progression in papillary renal cell carcinoma , 2014, Virchows Archiv.
[13] Y. Kanai,et al. Prognostic risk stratification of patients with urothelial carcinoma of the bladder with recurrence after radical cystectomy. , 2013, The Journal of urology.
[14] Jimin Gao,et al. A novel therapeutic vaccine of mouse GM-CSF surface modified MB49 cells against metastatic bladder cancer. , 2012, The Journal of urology.
[15] Y. Lotan,et al. Contemporary use of perioperative cisplatin‐based chemotherapy in patients with muscle‐invasive bladder cancer , 2011, Cancer.
[16] R. Wilcox. Cancer-associated myeloproliferation: old association, new therapeutic target. , 2010, Mayo Clinic proceedings.
[17] Bree L. Dority,et al. Comparison of hospitalization risk and associated costs among patients receiving sargramostim, filgrastim, and pegfilgrastim for chemotherapy‐Induced neutropenia , 2009, Cancer.
[18] E. Yu,et al. Rapid clinical deterioration and leukemoid reaction after treatment of urothelial carcinoma of the bladder: possible effect of granulocyte colony-stimulating factor. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[19] B. Reșorlu,et al. Muscle-invasive bladder cancer: predictive factors and prognostic difference between primary and progressive tumors. , 2007, Urology.
[20] G. Lyman,et al. Impact of primary prophylaxis with granulocyte colony-stimulating factor on febrile neutropenia and mortality in adult cancer patients receiving chemotherapy: a systematic review. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[21] K. Naito,et al. Direct and indirect effects of recombinant human granulocyte-colony stimulating factor on in vitro colony formation of human bladder cancer cells , 1994, Cancer Immunology, Immunotherapy.
[22] S. Saito,et al. Mirimostim (macrophage colony‐stimulating factor; M‐CSF) improves chemotherapy‐induced impaired natural killer cell activity, Th1/Th2 balance, and granulocyte function , 2003, Cancer science.
[23] D. Carlo,et al. Novel membrane-bound GM-CSF vaccines for the treatment of cancer: generation and evaluation of mbGM-CSF mouse B16F10 melanoma cell vaccine , 2002, Gene Therapy.
[24] T. Kitamura,et al. Bladder tumor producing granulocyte colony-stimulating factor and parathyroid hormone related protein. , 2002, The Journal of urology.
[25] M. Tanimoto,et al. Human urinary macrophage colony-stimulating factor reduces the incidence and duration of febrile neutropenia and shortens the period required to finish three courses of intensive consolidation therapy in acute myeloid leukemia: a double-blind controlled study. , 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[26] Y. Kakehi,et al. Serum granulocyte colony-stimulating factor levels in patients with urinary bladder tumour and various urological malignancies. , 1995, British journal of urology.
[27] T. Nishi,et al. Autocrine Growth of Transitional Cell Carcinoma of the Bladder Induced by Granulocyte-Colony Stimulating Factor 1 , 2006 .
[28] L. Yee,et al. FMS (CSF-1 receptor) and CSF-1 transcripts and protein are expressed by human breast carcinomas in vivo and in vitro. , 1991, Oncogene.